A pharmacovigilance analysis found different reporting patterns across hypnotics, but it cannot determine how often users develop misuse or dependence.
The study compared reports involving benzodiazepines, Z-drugs, orexin antagonists, and several other medicines used for insomnia. It calculated disproportionality measures for events related to abuse, dependence, and withdrawal. Some newer medication categories had lower reporting odds than selected comparators.
FAERS lacks a reliable denominator of exposed patients and is affected by underreporting, publicity, time on the market, indication, and duplicate or incomplete reports. Reporting odds are not patient risk ratios. The paper also disclosed pharmaceutical-company involvement, which belongs in an evidence appraisal.
An expert should describe the result as a reporting signal rather than a measured clinical abuse rate. It does not prove that one hypnotic is free of dependence risk or determine the correct regulatory category. Individual diagnosis requires actual behavior, exposure history, and clinical evidence beyond a database comparison.
Source reviewed: Real world data on the abuse potential of medications for the treatment of insomnia a disproportiona (PMC12891218). Forensic applications above are interpretive analysis of the supplied paper.
Related reading: Three-Drug ERCP Sedation Compared Age Groups Rather Than Isolated Medicines; Remimazolam FAERS Signals Were Reporting Patterns, Not Event Incidence.